{"filing":{"accession_number":"0001731122-26-001281","cik":"0001553788","ticker":"SBEVW","company_name":"Endovia Health Sciences, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-18","primary_document":"e7970_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001281/e7970_8k.htm"},"events":[{"id":34882,"run_id":32119,"accession_number":"0001731122-26-001281","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Endovia entered into a Letter Agreement with C/M Capital Master Fund on September 18, 2026, and issued a secured convertible promissory note with a principal amount of $576,271 (net of original issue discount) in exchange for $510,000 in gross proceeds. The Note is convertible into Common Stock at a specified conversion price, matures September 18, 2027, and is subject to mandatory prepayments.","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38742,"accession_number":"0001731122-26-001281","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Endovia entered into a Letter Agreement with C/M Capital Master Fund on September 18, 2026, pursuant to which the Company issued a secured convertible promissory note with a principal amount of $576,271 (net of original issue discount) in exchange for $510,000 in gross proceeds. The Note is convertible into Common Stock at a specified conversion price, matures September 18, 2027, and is subject to mandatory prepayments. This is a creation of a new direct financial obligation—a convertible debt instrument—which falls squarely within the debt_issuance category. The materiality is clear given the $510,000 investment commitment and the structured terms including conversion rights and mandatory prepayment provisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:14:42.272791+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":34883,"run_id":32119,"accession_number":"0001731122-26-001281","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Endovia completed an unregistered sale of 3,629,250 shares of common stock to an investor under an ELOC Agreement for approximately $809,000 in gross proceeds during August-September 2026, relying on Section 4(a)(2) and Rule 506(b) exemptions.","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38743,"accession_number":"0001731122-26-001281","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of 3,629,250 shares of common stock to an investor under an ELOC Agreement for approximately $809k in gross proceeds during August-September 2026. The transaction is explicitly characterized as an unregistered sale relying on Section 4(a)(2) and Rule 506(b) exemptions, which is the hallmark of a dilutive equity issuance. This represents material capital-raising activity that dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:14:42.272791+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38742,"accession_number":"0001731122-26-001281","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Endovia entered into a Letter Agreement with C/M Capital Master Fund on September 18, 2026, pursuant to which the Company issued a secured convertible promissory note with a principal amount of $576,271 (net of original issue discount) in exchange for $510,000 in gross proceeds. The Note is convertible into Common Stock at a specified conversion price, matures September 18, 2027, and is subject to mandatory prepayments. This is a creation of a new direct financial obligation—a convertible debt instrument—which falls squarely within the debt_issuance category. The materiality is clear given the $510,000 investment commitment and the structured terms including conversion rights and mandatory prepayment provisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:14:42.272791+00:00","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-09-24"},{"id":38743,"accession_number":"0001731122-26-001281","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses an unregistered sale of 3,629,250 shares of common stock to an investor under an ELOC Agreement for approximately $809k in gross proceeds during August-September 2026. The transaction is explicitly characterized as an unregistered sale relying on Section 4(a)(2) and Rule 506(b) exemptions, which is the hallmark of a dilutive equity issuance. This represents material capital-raising activity that dilutes existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:14:42.272791+00:00","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-09-24"}]}